Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 10:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 1,436 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Level B Clear all
Active, not recruiting Phase 1 Interventional

Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

NCT04898894
View directory record Official record
Conditions
Acute Leukemia of Ambiguous Lineage in Relapse, Acute Myeloid Leukemia, in Relapse, Refractory Acute Leukemia of Ambiguous Lineage, Refractory Acute Myeloid Leukemia
Interventions
Venetoclax, Selinexor, Cytarabine, Fludarabine, Filgrastim, Methotrexate, methotrexate/hydrocortisone/cytarabine
Drug · Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 30 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
8
States / cities
San Diego, California • Boston, Massachusetts • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 29, 2026, 10:59 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer

NCT01433172
View directory record Official record
Conditions
Lung Cancer, Adenocarcinoma
Interventions
Phase I - GM.CD40L.CCL21 Vaccinations, Phase II - GM.CD40L cells Vaccinations, Phase II - GM.CD40L.CCL21 Vaccinations
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 29, 2026, 10:59 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

MIRA CONNECT Study

NCT06802263
View directory record Official record
Conditions
Pregnancy of Unknown Location (PUL)
Interventions
at-home quantitative urine b-hCG test
Diagnostic Test
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 29, 2026, 10:59 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older

NCT03982199
View directory record Official record
Conditions
Respiratory Syncytial Viruses, Respiratory Tract Diseases
Interventions
RSV Vaccine, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
65 Years and older
Enrollment
5,815 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
40
States / cities
Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 29, 2026, 10:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Connecting Families to Overcome Ovarian Cancer

NCT04927013
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Message-based Outreach Intervention for Survivors, Standard Outreach for Survivors, Message-based Outreach Intervention for Close Relatives, Standard Outreach for Close Relatives
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
2,331 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 29, 2026, 10:59 AM EDT
Completed Phase 2 Interventional Results available

Hydroxychloroquine in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer

NCT00726596
View directory record Official record
Conditions
Prostate Cancer
Interventions
hydroxychloroquine
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older · Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
5
States / cities
Hamilton, New Jersey • Morristown, New Jersey • New Brunswick, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2022 · Synced Oct 29, 2026, 10:59 AM EDT
Completed Phase 2 Interventional Results available

Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load

NCT00515827
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir (MK-0518), Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
20
States / cities
Birmingham, Alabama • Palo Alto, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 29, 2026, 10:59 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Rapid UTI Diagnostics in Lower Urinary Tract Dysfunction Among Catheter Users

NCT07784829
View directory record Official record
Conditions
Neurogenic Bladder Disorder, Lower Urinary Tract Disorder, Urinary Tract Infection (Diagnosis)
Interventions
urine Resazurin Reduction Ratio, USQNB
Diagnostic Test · Other
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 29, 2026, 10:59 AM EDT
Terminated No phase listed Observational

Evaluation of a Simulation-Based Educational Tool for Personalized Feedback in Insulin Therapy Management

NCT01767831
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
iBOLUSED
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 28, 2014 · Synced Oct 29, 2026, 10:59 AM EDT
Completed Not applicable Interventional Results available

Cognitive Rehabilitation in Schizophrenia

NCT00248794
View directory record Official record
Conditions
Cognitive Impairment, Schizophrenia
Interventions
Cognitive Rehabilitation Therapy (CRT) + Skill Training (SDG), Individual Computer Based Cognitive Rehabilitation (ICBCR) and Skills Training (SDG), Skills Group (SDG)
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 25, 2016 · Synced Oct 29, 2026, 10:59 AM EDT
Completed Not applicable Interventional

Effect of Brief Dietary Intervention on Ammonia Levels

NCT05376488
View directory record Official record
Conditions
Cirrhosis, Hepatic Encephalopathy
Interventions
One meal
Other
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 29, 2026, 10:59 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)

NCT02568683
View directory record Official record
Conditions
Non-Hodgkin Lymphoma
Interventions
Entospletinib, Vincristine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Hattiesburg, Mississippi • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Oct 29, 2026, 10:59 AM EDT
Active, not recruiting Phase 1 Interventional

High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma

NCT01840566
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Carmustine, Etoposide, Cytarabine, Melphalan, Pegfilgrastim, 19-28z T CELLS, Autologous Stem Cell Transplantation
Drug · Biological · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 29, 2026, 10:59 AM EDT
Not listed Not applicable Interventional

Strategy + RehaCom for Memory Rehabilitation in Traumatic Brain Injury (TBI)

NCT04239456
View directory record Official record
Conditions
Traumatic Brain Injury With Loss of Consciousness
Interventions
RehaCom (software)
Device
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 29, 2026, 10:59 AM EDT
Recruiting Not applicable Interventional

Investigation of PEMF Therapy for Female Patients With IC/BPS

NCT05149573
View directory record Official record
Conditions
Interstitial Cystitis, Chronic Interstitial Cystitis, Bladder Pain Syndrome
Interventions
Pulsed Electromagnetic Field (PEMF) Device, Sham Pulsed Electromagnetic Field (PEMF) Device
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 29, 2026, 10:59 AM EDT
Completed Phase 1 Interventional

A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study

NCT01230853
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Active Comparator: A, Placebo Comparator B, Active Comparator B, Placebo Comparator A
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Garden Grove, California • San Francisco, California • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 29, 2026, 10:59 AM EDT
Terminated Not applicable Interventional Results available

SMILE: Clinical Trial to Evaluate Mindfulness as Intervention for Racial and Ethnic Populations During COVID-19

NCT06242080
View directory record Official record
Conditions
Anxiety, COVID-19 Pandemic
Interventions
Mindfulness
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 29, 2026, 10:59 AM EDT
Completed Phase 1 Interventional

Treatment of Chronic Lymphocytic B-Leukemia With IL-2 and CD-40 Autologous Tumor Cells

NCT00058786
View directory record Official record
Conditions
Chronic Lymphocytic B-Leukemia
Interventions
Injection of IL-2-secreting CD40L-expressing autologous B-CLL cells
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 23, 2012 · Synced Oct 29, 2026, 10:59 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

NCT05626322
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Maplirpacept, Tafasitamab, Lenalidomide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Baton Rouge, Louisiana • Ann Arbor, Michigan • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 29, 2026, 10:59 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Allogeneic Human Mesenchymal Stem Cell Injection in PAtieNts With FaceTogenic Back Pain

NCT03487731
View directory record Official record
Conditions
Facetogenic Back Pain, Back Pain
Interventions
Allogeneic Human Mesenchymal Stem Cells (hMSCs), Placebo
Biological · Drug
Lead sponsor
Joshua M Hare
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 29, 2026, 10:59 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase II Study of TAK228 in Relapsed Lymphoma

NCT02727777
View directory record Official record
Conditions
Lymphoma
Interventions
TAK228, Blood Sugar Testing
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Oct 29, 2026, 10:59 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants

NCT01318694
View directory record Official record
Conditions
Hepatitis C
Interventions
Alisporivir, Peginterferon alfa-2a, Ribavirin, ALV Placebo
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,081 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
32
States / cities
Beverly Hills, California • Oakland, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2016 · Synced Oct 29, 2026, 10:59 AM EDT
Completed Not applicable Interventional Results available

Scaling Up: A Multi-Site Trial of e-SBI for Alcohol Use in Pregnancy

NCT04332172
View directory record Official record
Conditions
Fetal Alcohol Spectrum Disorders, Fetal Alcohol Syndrome, Fetal Alcohol Effect
Interventions
General information, Baseline brief intervention, Remote online booster sessions, SMS
Other · Behavioral
Lead sponsor
Michigan State University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Flint, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 29, 2026, 10:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Peripheral Immune System in Individuals With Schizophrenia

NCT05109065
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder, Schizophreniform Disorders
Interventions
SCID (Standardized Clinical Interview for DSM-V), PSS (Perceived Stress Score), Urine Toxicology Screen, Vitals, Blood Work, PQ-B, COVID Screening, Positive and Negative Syndrome Scale (PANSS)
Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 40 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Oct 29, 2026, 10:59 AM EDT